ArticleCardiovascular diagnosis and therapy2017
Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.
Article in Cardiovascular diagnosis and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 51 citations in OpenAlex.
- Trial
- Reconceptualizing Dyslipidemia: Diversity of Lipid Imbalances and Their Clinical Implications; A Narrative Review.Health science reports · 2026Article
- Recent advances of self-assembled nanoparticles in the diagnosis and treatment of atherosclerosis.Theranostics · 2024Review
- Performance evaluation of Barozen Lipid Plus for point-of-care testing of lipid profiles: a method comparison study.Journal of Yeungnam medical science · 2023Article
- ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.Current atherosclerosis reports · 2022Review
- The Role of High-Density Lipoprotein Cholesterol in 2022.Current atherosclerosis reports · 2022Review
- CRISPR/dCas9 Transcriptional Activation of Endogenous Apolipoprotein AI and Paraoxonase 1 in Enterocytes Alleviates Endothelial Cell Dysfunction.Biomolecules · 2021Article
- Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis.Advanced drug delivery reviews · 2021Review
- Tackling cardiometabolic risk in the Asia Pacific region.American journal of preventive cardiology · 2020Review
- The role of intracoronary imaging in translational research.Cardiovascular diagnosis and therapy · 2020Review
- Phospholipid Component Defines Pharmacokinetic and Pharmacodynamic Properties of Synthetic High-Density Lipoproteins.The Journal of pharmacology and experimental therapeutics · 2020Article
- Advances in HDL: Much More than Lipid Transporters.International journal of molecular sciences · 2020Review
- Synergetic Effect of rHDL and LXR Agonist on Reduction of Atherosclerosis in Mice.Frontiers in pharmacology · 2020Article
- High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential.Frontiers in cardiovascular medicine · 2020Review
- Supramolecular Assembly of High-Density Lipoprotein Mimetic Nanoparticles Using Lipid-Conjugated Core Scaffolds.Journal of the American Chemical Society · 2019Article
- Intravenous toxicity and toxicokinetics of an HDL mimetic, Fx-5A peptide complex, in cynomolgus monkeys.Regulatory toxicology and pharmacology : RTP · 2018Article
- Reconstituted Discoidal High-Density Lipoproteins: Bioinspired Nanodiscs with Many Unexpected Applications.Current atherosclerosis reports · 2018Review
- Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis.Journal of personalized medicine · 2018Review
- HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?Current cardiology reports · 2018Review
- Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits.Arteriosclerosis, thrombosis, and vascular biology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 8 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-density lipoprotein (HDL) is believed to have atheroprotective properties, but an effective HDL-based therapy remains elusive. Early studies have suggested that infusion of reconstituted HDL promotes reverse cholesterol transport and vascular reactivity. The CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial (CARAT) is investigating the impact of infusing an engineered pre-beta HDL mimetic containing sphingomyelin (SM) and dipalmitoyl phosphatidlyglycerol (CER-001) on coronary atheroma volume in patients with a recent acute coronary syndrome (ACS).
methodsThe CARAT is a phase 2, multicenter trial in which 292 patients with an ACS undergoing intracoronary ultrasonography and showing percent atheroma volume (PAV) greater than 30% are randomly assigned to treatment with ten infusions of CER-001 3 mg/kg or matching placebo, administered at weekly intervals. Intracoronary ultrasonography is repeated at the end of the treatment period.
resultsThe primary endpoint is the nominal change in PAV. Safety and tolerability will also be evaluated.
conclusionsCARAT will establish whether serial 3 mg/kg infusions of an engineered pre-beta HDL mimetic containing SM and dipalmitoyl phosphatidlyglycerol (CER-001) will regress atherosclerotic plaque in patients with a recent ACS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.